Industry News

Search Articles:

Resverlogix repays $68.8 million loan
Resverlogix announced that it has repaid, in full, its CAD$68.8 million Loan. Upon repayment of the Loan, the Company has no outstanding long-term debt. Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective (bromodomain and extra-terminal) inhibitor.December 06, 2017